Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

J Immunother Cancer · 2019 · PMC6532211 · PMID 31118108

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The magnitude of induction was generally lower than that of patients who received ONC201 once weekly, though this did not reach statistical significance (Additional file 1 : Figure S2).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.